Tag: Chemoterapy

Onxeo encouraged by intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA in combination with chemotherapy
September 18, 2019 Off

Onxeo encouraged by intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA in combination with chemotherapy

By BusinessWire

Onxeo said it stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ plus carboplatin, with reaching satisfactory tolerance allowing the continuation of the study to evaluate AsiDNA™ in combination with carboplatin and paclitaxel, a reference treatment protocol for many cancers.

Merck, Pfizer dropping program from Phase III Javelin Ovarian PARP study
March 20, 2019 Off

Merck, Pfizer dropping program from Phase III Javelin Ovarian PARP study

By Dino Mustafić

German Merck, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer are dropping the Phase III JAVELIN Ovarian PARP 100 study in which they tested avelumab combined with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV), as they described in the press release on Wednesday.

FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
March 19, 2019 Off

FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer

By BusinessWire

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),today announced that the U.S. Food and Drug Administration (FDA)approved Tecentriq® (atezolizumab), in combinationwith carboplatin and etoposide (chemotherapy), for the initial(first-line) treatment of adults with extensive-stage small cell lungcancer (ES-SCLC).